DEXTROSE 50%

Post-LOE

dextrose monohydrate

Medica Corp

ANDAINJECTIONINJECTABLE

Approved

Mar 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DEXTROSE 50% (dextrose monohydrate) by Medica Corp is clinical pharmacology when administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories. Approved for the treatment of insulin hypoglycemia (hyperinsulinemia, insulin shock) to restore blood glucose levels. First approved in 2021.

Mechanism of Action

CLINICAL PHARMACOLOGY When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose…

Indications (2)

the treatment of insulin hypoglycemia (hyperinsulinemia

Worked on DEXTROSE 50% at Medica Corp? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.